With the discovery of specific tyrosine kinase inhibitors (TKIs) against BCR-ABL, the therapy of CML changed dramatically from a dismal to a very favorable outcome [3]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.